June 16, 2017 — The U.S. Food and Drug Administration (FDA) has expanded the indication for GE Healthcare’s imaging agent Visipaque (iodixanol) Injection. Visipaque 320 mg iodine/mL is an iso-osmolar agent that is now approved for use in coronary computed tomography angiography (CCTA) to assist in the diagnostic evaluation of adult and pediatric patients 12 years of age or older with suspected coronary artery disease in the United States.

The U.S. Food and Drug Administration (FDA) has cleared the Magnetom Vida 3 Tesla (3T) magnetic resonance imaging (MRI) scanner from Siemens Healthineers, which features new BioMatrix technology that addresses inherent anatomical and physiological differences among patients, as well as user variability.

RamSoft announced its distribution partnership with KenQuest Medical. With RamSoft’s PowerServer and Gateway solutions, KenQuest Medical will offer clinics a software solution that can be customized to fit their workflow, enhance patient care, and ensure minimal downtime to fulfill their image management, storage, and distribution needs from a trusted source at competitive prices. 

Researchers from the University of Luxembourg, in cooperation with the University of Strasbourg, have developed a computational method that could be used to guide surgeons during brain surgery.

During the first quarter of 2017, Black Book surveyed 140 chief information officers (CIOs), 159 chief financial officers (CFOs) and 448 hospital managers involved in planning and executing population health initiatives within the next 12 months. Ninety percent of the collective respondents revealed that future population health management (PHM) systems will essentially be projected to perform as next-generation patient accounting systems.

An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific molecular imaging gives these men a fighting chance, especially if their cancer returns, according to research revealed at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may have a high clinical impact on outcomes. Researchers at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrated preclinically that dual-labeled PSMA-inhibitors based on PSMA-11 enhance preoperative staging, using PET/CT followed by fluorescence-guided surgery. 

Pancreatic cancer is associated with bleak five-year survival rates and limited treatment options, but new research is offering hope. A first-in-human study presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrates the feasibility and safety of the novel human monoclonal antibody HuMab-5B1 with highly specific targeting for the cancer antigen (CA) 19-9, which is expressed on pancreatic tumors and a variety of other malignancies, including small cell lung cancer and tumors of the gastrointestinal system.

More people die of Alzheimer's disease than prostate and breast cancer combined. Identifying the disease before major symptoms arise is critical to preserving brain function and helping patients maintain quality of life. A new study presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrates that a single dual time-point PET scan could identify important biomarkers of Alzheimer's disease.

Despite evidence showing that the routine use of sonography in hospital emergency departments can safely improve care for adults when evaluating for possible abdominal trauma injuries, researchers at UC Davis Medical Center could not identify any significant improvements in care for pediatric trauma patients.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now